Patrick O'Brien Arrowhead Pharmaceuticals, Inc. (ARWR) insider trading activity

Patrick O'Brien is COO of ARROWHEAD PHARMACEUTICALS, INC.. Currently has a direct ownership of 472,408 shares of ARWR, which is worth approximately $19.5 Million. The most recent transaction as insider was on Jan 06, 2026, when has been sold 2,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 472K

10.39% 3M change

10.39% 12M change

Total Value Held $19.5 Million

Patrick O'Brien Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	SELL Bona fide gift	-	2,500 Reduced 0.53%	472,408 Common Stock
Jan 06 2026	BUY Grant, award, or other acquisition	-	75,000 Added 12.05%	547,408 Common Stock
Jan 05 2026	SELL Open market or private sale	$3,163,592 $63.92 p/Share	49,493 Reduced 9.44%	474,908 Common Stock
Dec 31 2025	SELL Bona fide gift	-	2,800 Reduced 0.53%	524,401 Common Stock
Jan 07 2025	SELL Open market or private sale	$157,520 $19.69 p/Share	8,000 Reduced 1.49%	527,201 Common Stock
Jan 06 2025	SELL Open market or private sale	$580,761 $19.9 p/Share	29,184 Reduced 5.17%	535,201 Common Stock
Jan 04 2025	BUY Grant, award, or other acquisition	-	100,000 Added 15.05%	564,385 Common Stock

Jan 05 2024	SELL Open market or private sale	$796,694 $34.88 p/Share	22,841 Reduced 4.69%	464,385 Common Stock
Jan 04 2024	SELL Open market or private sale	$52,208 $32.63 p/Share	1,600 Reduced 0.4%	402,226 Common Stock
Jan 04 2024	BUY Grant, award, or other acquisition	-	85,000 Added 14.85%	487,226 Common Stock
Jan 03 2024	SELL Open market or private sale	$285,217 $32.6 p/Share	8,749 Reduced 2.12%	403,826 Common Stock
Jan 05 2023	SELL Open market or private sale	$560,850 $37.39 p/Share	15,000 Reduced 3.5%	413,375 Common Stock
Jan 04 2023	BUY Grant, award, or other acquisition	-	65,000 Added 13.17%	428,375 Common Stock
Jan 03 2023	SELL Open market or private sale	$684,425 $39.11 p/Share	17,500 Reduced 4.59%	363,375 Common Stock
Dec 21 2022	BUY Exercise of conversion of derivative security	$196,800 $6.15 p/Share	32,000 Added 7.75%	380,875 Common Stock
Jan 05 2022	SELL Open market or private sale	$2,034,175 $62.59 p/Share	32,500 Reduced 8.52%	348,875 Common Stock
Jan 01 2022	BUY Grant, award, or other acquisition	-	60,000 Added 13.59%	381,375 Common Stock
Dec 31 2021	BUY Exercise of conversion of derivative security	$172,200 $6.15 p/Share	28,000 Added 8.01%	321,375 Common Stock
Feb 08 2021	SELL Open market or private sale	$7,950,600 $88.34 p/Share	90,000 Reduced 23.48%	293,375 Common Stock
Feb 08 2021	BUY Exercise of conversion of derivative security	$469,800 $5.22 p/Share	90,000 Added 19.01%	383,375 Common Stock
Jan 06 2021	SELL Open market or private sale	$1,797,750 $71.91 p/Share	25,000 Reduced 7.85%	293,375 Common Stock
Jan 01 2021	BUY Grant, award, or other acquisition	-	60,000 Added 15.86%	318,375 Common Stock
Dec 04 2020	SELL Bona fide gift	-	800 Reduced 0.23%	348,075 Common Stock

Patrick O'Brien

COO

Pasadena, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARWR shares.

Notify only if

Value

Insider Trading

Get notified when an Arrowhead Pharmaceuticals, Inc. insider buys or sells ARWR shares.

Notify only if

Operation

Value

Type

News

Receive news related to ARROWHEAD PHARMACEUTICALS, INC.

Track Activities on ARWR

Account